Centessa Q2 net loss $24.9M; cash $303.6M; SerpinPC registrational study dosing

Centessa Pharmaceuticals plc

2023-Q2 EPS reported -$0.80

Cash, equivalents and short-term investments $303.6M as of June 30; plus $15M ATM gross proceeds in Aug 2023; runway into 2026.
Net loss $24.9M vs $64.7M YoY, including $24.1M tax benefit from valuation allowance release on deferred tax assets.
R&D expenses $33.7M (Q2 2023) vs $53.7M (Q2 2022); G&A $13.3M vs $14.8M.
SerpinPC registrational PRESent-2 study first subject dosed July 2023; FDA Fast Track designation received May 2023.
LB206 (PD-L1xCD3 LockBody) nominated as second development candidate; ORX750 IND-enabling; preclinical data at World Sleep Congress Oct 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Centessa Pharmaceuticals plc reported for the second quarter ended June 30, 2023 results: net income $24.9 million.

Period: for the second quarter ended June 30, 2023
Net income: $24.9 million
Result: reported results

Exact text from the filing

Centessa Pharmaceuticals plc (the "Company") announced its financial results for the quarter ended June 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-23-000153

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.